Interactive computerized microscopy as a tool for quantifying vascular remodelling: Effects of diabetes and V1a receptor antagonist SR 49059 on rat mesenteric arterial bed

Journal of Pharmacological and Toxicological Methods

Volumn 41, Issue 2-3, 1999, Pages 59-67

  Mechaly I ^a   Krosniak, M ^a   Azay, J ^a   Cassanas, G ^a   Roque, C ^b   Cahard, D ^b   Serrano, J J ^a   Cros, G ^a  

^a UNIV MONTPELLIER   (France)

^b SANOFI   (France)

Author keywords

Computerized histomorphometry; Diabetes; Mesenteric arteries; Vasopressin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; RELCOVAPTAN; VASOPRESSIN; VASOPRESSIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR SYSTEM; COMPUTER ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MESENTERIC ARTERY; MICROSCOPY; MORPHOMETRICS; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STREPTOZOCIN DIABETES;

ANIMALIA;

EID: 0344211036     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(99)00021-0     Document Type: Article

References (31)

1. Bohlen H.G., Hankins K.D. Early arteriolar and capillary changes in streptozotocin-induced diabetic rats and intraperitoneal hyperglycaemic rats. Diabetologia. 22:1982;344-348.
2. Brooks D.P., Nutting J.T., Crofton J.T., Share L. Vasopressin in rats with genetic and streptozotocin-induced diabetes. Diabetes. 38:1989;54-57.
3. Brugal G., Dye R., Krief B., Chassery J.-M., Tanke H., Tucker H. Home. Highly optimized microscope environment Cytometry. 13:1992;109-116.
4. Burlet A.J., Jhanwar-Uniyal M., Chapleur-Chateau M., Burlet C.R., Leibowitz S.F. Effect of food deprivation and refeeding on the concentration of vasopressin and oxytocin in discrete hypothalamic sites. Pharmacol Biochem Behav. 43:1992;897-905.
5. Buwalda B., Nyakas C., Koolhaas M., Bohus B. Neuroendocrine and behavioral effects of vasopressin in resting and mild stress conditions. Physiol Behav. 54:1993;947-953.
6. Cooper M.E., Rumble J., Komers R., He-Cheng D., Kandeleit K., Sheung-To C. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes. 43:1994;1221-1228.
7. Geisterfer A.A.T., Peacg M.J., Owens G.K. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 62:1988;749-756.
8. Harano A., Hidaka H., Kojima H., Harano Y., Shigeta Y. Suppressive effect of vasopressin on ketosis in diabetic rats. Horm Metab Res. 24:1992;5-9.
9. Herbert V., Lau K.S., Gottlieb C.W., Bleicher S.J. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab. 25:1965;1375-1384.
10. Jandeleit K., Rumble J., Jackson B., Cooper M.E. Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitus. Clin Exp Pharmacol Physiol. 19:1992;343-347.
11. Kamoi K., Ishibashi M., Yamaji T. Thirst and plasma levels of vasopressin, angiotensin II and atrial natriuretic peptide in patients with non-insulin-dependent diabetes mellitus. Diab Res Clin Pract. 11:1991;195-202.
12. Kiff R.J., Gardiner S.M., Compton A.M., Bennett T. Selective impairment of hindquarter vasodilator responses to bradykinin in conscious wistar rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol. 103:1991;1357-1362. a.
13. Kiff R.J., Gardiner S.M., Compton A.M., Bennett T. The effects of endothelin-1 and NG-nitro-L-arginine methyl ester on regional haemodynamics in conscious rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol. 103:1991;1321-1326. b.
14. Langhans W., Deprete E., Scharrer E. Mechanism of vasopressin's anorectic effect. Physiol Behav. 49:1991;169-176.
15. Lee R.M.K.W., Garfield R.E., Forrest J.B., Daniel E.E. Morphometric study of structural changes in the mesenteric blood vessels of spontaneously hypertensive rats. Blood Vessels. 20:1983;57-71.
16. Lee R.M.K.W. Vascular changes at the prehypertensive phase in the mesenteric arteries from spontaneously hypertensive rats. Blood Vessels. 22:1985;105-126.
17. Max J.P., Thystere P., Chapleur-Chateau M., Burlet A., Nicolas J.P., Burlet C. Hypothalamic neuropeptides could mediate the anorectic effects of fenfluramine. Neuroreport. 5:1994;1925-1928.
18. Méchaly I., Macary F., Lautier C., Serrano J.J., Cros G., Grigorescu F. Identification and sequence analysis of arginine vasopressin mRNA in normal and Brattleboro rat aortic tissue. Eur J Endocrinol. 139:1998;123-126.
19. Murase T., Kozawa O., Miwa M., Tokuda H., Kotoyori J., Kondo K., Oiso Y. Regulation of proliferation by vasopressin in aortic smooth muscle cells. function of protein kinase C J Hypertens. 10:1992;1505-1511.
20. 4 treatment. persistence of insulin secreting capacities assessed by isolated pancreas studies Mol Cell Biochem. 153:1995;197-204.
21. Rumble J.R., Komers R., Cooper M.E. Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin-converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens. 14:1996;601-607.
22. Serradeil-Le Gal C., Herbert J.M., Delisée C., Schaeffer P., Raufaste D., Garcia C., Dol F., Marty J.P., Maffrand J.P., Le Fur G. Effect of SR 49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells. Am J Physiol. 268:1995;H404-H410.
23. Serradeil-Le Gal C., Wagnon J., Garcia C., Lacour C., Guiraudou P., Christophe B., Villanova G., Nisato D., Maffrand J.P., LeFur G., Guillon G., Cantau B., Barberis C., Trueba M., Jard S. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest. 92:1993;224-231.
24. Shi Y., Pienek M., Fard A., 0'Brien J., Mannion J.D., Zalewski A. Adventicial remodeling after coronary arterial injury. Circulation. 93:1996;340-348.
25. Simon J.S., Baum J.S., Moore S.A., Kasson B.G. Arginine vasopressin stimulates protein synthesis but not proliferation of cultured vascular endothelial cells. J Cardiovasc Pharmacol. 25:1995;368-375.
26. Simon J.S., Brody M.J., Kasson B.G. Characterization of a vasopressin-like peptide in rat and bovine blood vessels. Am J Physiol. 262:1992;H799-H804.
27. Tallroth G., Ryding E., Ekman R., Agardh C.D. The response of regulatory peptides to moderate hypoglycaemia of short duration in type 1 (insulin-dependent) diabetes mellitus and in normal man. Diab Res. 20:1992;73-85.
28. Trinder D., Phillips P.A., Stephenson J.M., Risvanis J.K., Aminian A., Adam W., Cooper M., Johnston C.I. Vasopressin V1 and V2 receptors in diabetes mellitus. Am J Physiol. 266:1994;E217-E223.
29. Unthank J.L., Bohlen H.G. Intestinal microvascular growth during maturation in diabetic juvenile rats. Circ Res. 63:1988;429-436.
30. Vacher E., Richer C., Cazaubon C., Fornes P., Nisato D., Giudicelli J.F. Are vasopressin peripheral V1 receptors involved in the development of malignant hypertension and stroke in SHR-SPs? Fund Clin Pharmacol. 9:1995;469-478.
31. Vranes D., Cooper M.E., Dilley R.J. Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy. morphometric studies J Vasc Res. 32:1995;183-189.